Suven Life Sciences Limited (SUVEN.BO)
INR 122.4
(2.38%)
INR 122.4
(2.38%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1.05 Billion INR | 11.15% |
| 2022 | -1.18 Billion INR | 3.06% |
| 2021 | -1.21 Billion INR | -69.08% |
| 2020 | -721.51 Million INR | 23.42% |
| 2019 | -942.17 Million INR | -294.15% |
| 2018 | -239.04 Million INR | -119.33% |
| 2017 | 1.23 Billion INR | 41.86% |
| 2016 | 871.87 Million INR | 21.35% |
| 2015 | 718.48 Million INR | -33.93% |
| 2014 | 1.08 Billion INR | -24.56% |
| 2013 | 1.44 Billion INR | 367.44% |
| 2012 | 308.39 Million INR | 114.72% |
| 2011 | 143.62 Million INR | 40.37% |
| 2010 | 102.31 Million INR | 46.16% |
| 2009 | 70 Million INR | -1.71% |
| 2008 | 71.22 Million INR | -14.74% |
| 2007 | 83.53 Million INR | -25.84% |
| 2006 | 112.64 Million INR | 76.35% |
| 2005 | 63.87 Million INR | 165.47% |
| 2004 | 24.06 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -496.43 Million INR | -77.05% |
| 2024 Q1 | -280.39 Million INR | -5.65% |
| 2023 FY | -1.05 Billion INR | 11.15% |
| 2023 Q4 | -265.4 Million INR | 36.45% |
| 2023 Q1 | -240.9 Million INR | 12.86% |
| 2023 Q3 | -417.64 Million INR | -229.37% |
| 2023 Q2 | -126.8 Million INR | 47.36% |
| 2022 Q3 | -511.15 Million INR | -120.5% |
| 2022 FY | -1.18 Billion INR | 3.06% |
| 2022 Q2 | -231.81 Million INR | -41.99% |
| 2022 Q4 | -276.44 Million INR | 45.92% |
| 2022 Q1 | -163.26 Million INR | 21.5% |
| 2021 Q1 | -392.08 Million INR | -81.42% |
| 2021 FY | -1.21 Billion INR | -69.08% |
| 2021 Q4 | -207.98 Million INR | 38.27% |
| 2021 Q3 | -336.9 Million INR | -19.05% |
| 2021 Q2 | -282.98 Million INR | 27.83% |
| 2020 Q1 | -104.89 Million INR | 58.96% |
| 2020 Q2 | -156.56 Million INR | -49.26% |
| 2020 Q3 | -243.92 Million INR | -55.8% |
| 2020 Q4 | -216.12 Million INR | 11.4% |
| 2020 FY | -721.51 Million INR | 23.42% |
| 2019 Q4 | -255.58 Million INR | -12.03% |
| 2019 FY | -942.17 Million INR | -294.15% |
| 2019 Q3 | -228.13 Million INR | -15.14% |
| 2019 Q1 | -260.33 Million INR | -136.45% |
| 2019 Q2 | -198.13 Million INR | 23.89% |
| 2018 Q4 | 714.15 Million INR | 595.93% |
| 2018 Q1 | 260.24 Million INR | 0.0% |
| 2018 Q3 | -144 Million INR | -472.49% |
| 2018 Q2 | 38.66 Million INR | -85.14% |
| 2018 FY | -239.04 Million INR | -119.33% |
| 2017 FY | 1.23 Billion INR | 41.86% |
| 2016 FY | 871.87 Million INR | 21.35% |
| 2016 Q4 | 400.69 Million INR | 0.0% |
| 2015 Q3 | 177.19 Million INR | -28.34% |
| 2015 Q4 | 371.78 Million INR | 109.82% |
| 2015 FY | 718.48 Million INR | -33.93% |
| 2015 Q2 | 247.28 Million INR | 22.23% |
| 2015 Q1 | 202.3 Million INR | 19.36% |
| 2014 Q2 | 248.36 Million INR | -28.5% |
| 2014 Q1 | 347.38 Million INR | 7.2% |
| 2014 FY | 1.08 Billion INR | -24.56% |
| 2014 Q4 | 169.49 Million INR | -47.41% |
| 2014 Q3 | 322.26 Million INR | 29.75% |
| 2013 Q1 | 297.71 Million INR | 244.97% |
| 2013 Q4 | 324.05 Million INR | -11.05% |
| 2013 Q3 | 364.33 Million INR | -20.01% |
| 2013 FY | 1.44 Billion INR | 367.44% |
| 2013 Q2 | 455.46 Million INR | 52.99% |
| 2012 Q3 | 77.56 Million INR | 19.54% |
| 2012 Q4 | 86.3 Million INR | 11.26% |
| 2012 FY | 308.39 Million INR | 114.72% |
| 2012 Q1 | 79.63 Million INR | 0.0% |
| 2012 Q2 | 64.88 Million INR | -18.52% |
| 2011 FY | 143.62 Million INR | 40.37% |
| 2010 FY | 102.31 Million INR | 46.16% |
| 2009 FY | 70 Million INR | -1.71% |
| 2008 FY | 71.22 Million INR | -14.74% |
| 2007 FY | 83.53 Million INR | -25.84% |
| 2006 FY | 112.64 Million INR | 76.35% |
| 2005 FY | 63.87 Million INR | 165.47% |
| 2004 FY | 24.06 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 101.097% |
| NATCO Pharma Limited | 13.88 Billion INR | 107.569% |
| Suven Pharmaceuticals Limited | 3 Billion INR | 134.993% |
| Syncom Formulations (India) Limited | 253.14 Million INR | 515.088% |
| Achyut Healthcare Limited | 5.73 Million INR | 18431.525% |
| Ajanta Pharma Limited | 8.16 Billion INR | 112.874% |
| Alkem Laboratories Limited | 17.95 Billion INR | 105.851% |
| Alpa Laboratories Limited | 167.76 Million INR | 726.33% |
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 117.063% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | 165.059% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 103.312% |
| Bajaj HealthCare Limited | -837.93 Million INR | -25.4% |
| Bliss GVS Pharma Limited | 754.54 Million INR | 239.259% |
| Brooks Laboratories Limited | -195.91 Million INR | -436.325% |
| Divi's Laboratories Limited | 16 Billion INR | 106.567% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 101.887% |
| Eris Lifesciences Limited | 3.91 Billion INR | 126.806% |
| FDC Limited | 3.05 Billion INR | 134.426% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 93.003% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 122.314% |
| Granules India Limited | 4.05 Billion INR | 125.925% |
| Gufic Biosciences Limited | 861.35 Million INR | 221.989% |
| Hester Biosciences Limited | 188.89 Million INR | 656.283% |
| Indoco Remedies Limited | 984.6 Million INR | 206.72% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 124.961% |
| Ipca Laboratories Limited | 5.47 Billion INR | 119.197% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | 567.775% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | -432.614% |
| Lasa Supergenerics Limited | -217.3 Million INR | -383.541% |
| Laurus Labs Limited | 1.6 Billion INR | 165.448% |
| Lupin Limited | 19.14 Billion INR | 105.489% |
| Mankind Pharma Limited | 19.12 Billion INR | 105.493% |
| Medicamen Biotech Limited | 109.31 Million INR | 1061.269% |
| Medico Remedies Limited | 82.9 Million INR | 1367.369% |
| Megasoft Limited | -127.46 Million INR | -724.348% |
| Piramal Pharma Limited | 178.2 Million INR | 689.654% |
| RPG Life Sciences Limited | 876.6 Million INR | 219.868% |
| Sigachi Industries Limited | 571.8 Million INR | 283.763% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 72.864% |
| Unichem Laboratories Limited | -704.74 Million INR | -49.099% |
| Wanbury Limited | 559.56 Million INR | 287.783% |
| Windlas Biotech Limited | 581.87 Million INR | 280.584% |
| ZIM Laboratories Limited | 172.46 Million INR | 709.265% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 102.723% |
| Procter & Gamble Health Limited | 2 Billion INR | 152.282% |
| Amrutanjan Health Care Limited | 449.72 Million INR | 333.645% |
| Bal Pharma Limited | 73.92 Million INR | 1521.448% |
| Strides Pharma Science Limited | -706.14 Million INR | -48.804% |
| Venus Remedies Limited | 284.9 Million INR | 468.808% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | 148.444% |
| Nectar Lifesciences Limited | 49.95 Million INR | 2203.63% |
| Shilpa Medicare Limited | 318.74 Million INR | 429.659% |
| Aarti Drugs Limited | 1.71 Billion INR | 161.298% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | 178.164% |
| Ind-Swift Limited | 142.31 Million INR | 838.346% |
| Valiant Laboratories Limited | 3.19 Million INR | 32977.441% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 119.014% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 81.481% |
| Themis Medicare Limited | 435.23 Million INR | 341.423% |
| Hikal Limited | 696.02 Million INR | 250.967% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 106.344% |
| Sequent Scientific Limited | -358.69 Million INR | -192.945% |
| Novartis India Limited | 851.9 Million INR | 223.343% |
| Wockhardt Limited | -4.63 Billion INR | 77.305% |
| Jubilant Pharmova Limited | 771 Million INR | 236.286% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | 14916.173% |
| Neuland Laboratories Limited | 3 Billion INR | 135.016% |
| Morepen Laboratories Limited | 961.59 Million INR | 209.272% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | 819.632% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | -1058.287% |